Cholera vaccination campaign still stalled in Haiti, NPR reports

A planned mass cholera vaccination project in Haiti continues to be "bogged down in bureaucratic red tape," as spring rains begin and the number of cholera cases starts to rise, NPR's health blog "Shots" reports. The Haitian medical group GHESKIO and international health organization Partners In Health are organizing the vaccination campaign, which "is awaiting approval from a national ethics committee, which wants assurance that the vaccine is no longer considered experimental," according to the news service, which notes the "WHO last November approved the dollar-a-dose vaccine that's ready to be used in Haiti."

NPR describes an ongoing education campaign to raise awareness of the disease and gauge public interest in the vaccine, as well as a cholera treatment center. "If the project does go forward, however, proponents will face another hurdle," as "the planned vaccination project will reach only about one percent of the Haitian population," NPR reports. However, "[t]o bring cholera under control, experts figure they'll need to vaccinate millions of people at high risk of cholera -- before next year's rainy season," the news service writes (Knox, 3/27).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Argonne receives $21.7 million to advance cancer and vaccine discoveries